Adaptive Therapy

DRUG2 trials

Sponsors

The Christie NHS Foundation Trust, Peking University Cancer Hospital & Institute

Conditions

MelanomaNSCLC

Phase 2

Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy

Not yet recruitingNCT06470880

The Christie NHS Foundation TrustMelanoma

Start: 2024-06-30End: 2027-06-30Target: 40Updated: 2024-06-24

Unknown Phase

Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD

RecruitingNCT06924710

Peking University Cancer Hospital & InstituteNSCLC

Start: 2025-04-06End: 2029-12-31Target: 286Updated: 2025-10-02

Related Papers

Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer

BMJ Open2024-12-017 citations